Curatis Holding AG (CURN)

Overview

Curatis Holding AG is a pioneering company engaged in the acquisition, development, and commercialization of innovative medicines aimed at the prevention, diagnosis, and treatment of rare and specialty care diseases. The company is dedicated to addressing unmet medical needs, providing advanced therapeutic solutions in multiple therapeutic areas, such as oncology, neurology, pain management, and infectious diseases. Headquartered in Liestal, Switzerland, Curatis Holding AG is focused on clinical development and delivering effective treatments for patients facing unique health challenges.

Products and Services

• Fentanyl: A potent opioid used for managing severe pain, particularly in chronic pain and cancer-related pain contexts.
• Breakthrough Pain Treatment: Specialized medication aimed at relieving episodes of pain that occur despite ongoing pain management.
• Antiplatelet Agents: Medications designed to prevent blood clots and reduce the risk of stroke and heart attack in at-risk patients.
• Metastatic Hormone Receptor-Positive Breast Cancer Therapy: Treatments specifically formulated for advanced breast cancer that is hormone receptor-positive.
• Anti-Arrhythmic Drugs: Medications used to restore normal heart rhythm in patients with arrhythmias.
• Nasal Oil: A delivery method for medications targeting nasal conditions, enhancing absorption and efficacy.
• Wilson's Disease Treatment: Specific therapies for managing this genetic disorder that leads to copper accumulation in the body.
• Cyanide Poisoning Antidote: Essential treatments aimed at counteracting the effects of cyanide exposure.
• Digoxin Toxicity Management: Therapies tailored to mitigate the adverse effects of digoxin overdose in patients.
• Antihypotensive Agents: Medications to manage low blood pressure in various clinical scenarios.
• Bladder Pain Syndrome/Interstitial Cystitis Treatments: Specialized therapies aimed at relieving chronic pelvic pain associated with these conditions.
• Antibiotics: Broad-spectrum medications for treating bacterial infections across diverse medical contexts.
• Diagnostic Ophthalmology Services: Advanced diagnostic tools and services for assessing eye health and pathology.
• Antiviral Agents: Medications aimed at treating viral infections, providing therapeutic options for various viral illnesses.
• Ophthalmic Antibioticum: Targeted antibiotics formulated for treating eye infections.
• Gentamycin Collagen Sponge: A localized delivery system for gentamycin, enhancing treatment for targeted conditions.
• Benign Prostatic Hyperplasia Treatments: Therapeutic options to manage symptoms associated with prostate enlargement.
• Immunomodulators: Drugs that modify immune system responses for treating autoimmune diseases and related conditions.
• Epilepsy Management Solutions: Comprehensive treatments aimed at controlling the occurrence of seizures.
• Essential Tremor Treatments: Therapeutic options to alleviate involuntary shaking associated with this movement disorder.
• Thyreostatic Agents: Medications that inhibit thyroid hormone production for hyperthyroid conditions.
• Hereditary Tyrosinemia Type 1 Treatment: Specialized therapies addressing this rare genetic disorder affecting the metabolism of tyrosine.
• Nootropics: Cognitive enhancers that aim to improve memory and cognitive function.
• Tranquilizers: Medications used for their calming effects, often prescribed for anxiety disorders.
• Helicobacter Pylori Test: Diagnostic services for evaluating H. pylori infection, which can lead to ulcers.
• Phosphate Binders: Drugs used specifically for managing elevated phosphate levels in patients with kidney disease.
• Special Nutrition for Dialysis Patients: Nutrition solutions tailored for individuals undergoing dialysis treatment.
• Dermato Corticosteroids: Medications designed to reduce inflammation and irritation in skin conditions.
• Heavy Metal Poisoning Treatments: Therapies aimed at treating lead and mercury toxicity.
• Corticostimulin: A treatment designed to support adrenal function and overall wellbeing.
• Anti-Fog Agent: A specialized formula aimed at preventing fogging on surfaces like goggles and lenses.
• Chorea Associated with Huntington's Disease Treatments: Focused therapies to manage involuntary movements in affected patients.
• Antiepileptic Drugs: A wide range of medications aimed at preventing seizures in epilepsy patients.
• C-PTBE-01: Currently in Phase IIb clinical trial for the treatment of peritumoral brain edema.
• C-AM-01: In Phase IIa clinical trial for prevention of severe migraine with aura.
• C-MOH-01: Under Phase IIa clinical trial for treatment and prevention of medication overuse headache.
• C-FI-01: A candidate in Phase I clinical trial for fibrotic or inflammatory orphan diseases.